Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05772273 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

Name: PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT — clinical trial record (NCT05772273)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhaseNot applicable

SponsorThe First Affiliated Hospital of Soochow University

Started2023-03-15

View on ClinicalTrials.gov ↗

This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantation

Amendment history 2 changes detected by DataLookout

2026-09-03

Primary completion pushed: 2026-07-01 → 2027-07-01

2026-09-03

Completion pushed: 2026-12-31 → 2027-12-31

Trial Details

NCT Number	NCT05772273
Lead Sponsor	The First Affiliated Hospital of Soochow University Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions	Acute Myeloid Leukemia
Enrollment	43 participants
Start Date	2023-03-15
Primary Completion	2027-07-01 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-02